HPLC + MS
Independently tested for identity and purity
NP-TESA-002
Jun 24, 2026
99.82%
View Certificate of Analysis
CAS# 218949-48-5
Also Known As TH9507
Class Full-Length GHRH Analogue / GHRHR Agonist
Form Lyophilized Powder
Receptor Target
Peptide Length
Molecular Weight
Tesamorelin (TH9507, CAS# 218949-48-5) is a synthetic analogue of human growth hormone releasing hormone (hGHRH) comprising the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid group conjugated at the N-terminus. This N-terminal modification confers enhanced resistance to dipeptidyl peptidase IV (DPP-IV) enzymatic cleavage while preserving full GHRHR binding activity, making Tesamorelin a distinct pharmacological research tool compared to shorter GHRH fragments such as Sermorelin (29 AA) or Mod GRF 1-29. Supplied by NexPept as a lyophilized powder for in vitro laboratory research use. This compound has not been authorized by Health Canada for any therapeutic, clinical, or human use.
Molecular Profile
CAS#, sequence, N-terminal modification, molecular weight
CAS#, sequence, N-terminal modification, molecular weight
| Property | Value |
|---|---|
| CAS Number | 218949-48-5 |
| Research Designation | TH9507 |
| Compound Class | Synthetic full-length GHRH analogue — N-terminally modified GHRHR agonist |
| Sequence Length | 44 amino acids (full-length human GHRH sequence) |
| N-Terminal Modification | trans-3-hexenoic acid conjugate — confers DPP-IV enzymatic stability |
| Approximate MW | ~5135.8 Da |
| Receptor Target | GHRHR (Growth Hormone Releasing Hormone Receptor) |
| Key Distinction | Full 44-AA GHRH sequence + N-terminal stability modification; longer than Sermorelin (29 AA) and Mod GRF 1-29 analogues |
| Physical Form | Lyophilized powder |
| Analytical Method | High-Performance Liquid Chromatography (HPLC) + Mass Spectrometry (MS) |
| Appearance | White to off-white lyophilized solid |
In Vitro Research Context
Receptor pharmacology & N-terminal modification — laboratory use only
Receptor pharmacology & N-terminal modification — laboratory use only
A G protein-coupled receptor (GPCR) that mediates the effects of endogenous GHRH via cAMP/PKA signalling cascades in pituitary cell models. Tesamorelin binds GHRHR with full-agonist activity across the complete 44-AA GHRH sequence, enabling research applications that examine the contribution of the full peptide length — and each sequence segment — to receptor engagement kinetics and downstream signalling, which shorter GHRH fragments cannot fully replicate.
Tesamorelin’s trans-3-hexenoic acid group is conjugated to the N-terminus of the full 44-AA GHRH sequence. This modification sterically shields the Tyr¹-Ala² dipeptide from cleavage by dipeptidyl peptidase IV (DPP-IV), the enzyme responsible for rapid inactivation of unmodified GHRH in biological systems. The modification is studied in the context of DPP-IV stability assays, N-terminal conjugation effects on GHRHR binding kinetics, and comparative stability profiling of GHRH analogues.
Tesamorelin is studied in preclinical in vitro settings as a DPP-IV-resistant, full-length GHRH analogue. Its research utility spans GHRHR pharmacology, comparative GHRH analogue structure–activity studies, and N-terminal modification effects on peptide stability and receptor binding. The table below positions Tesamorelin relative to the other GHRH-class compounds in the NexPept catalogue:
| Compound | Length | Key Structural Feature | Signalling Profile |
|---|---|---|---|
| Sermorelin | 29 AA | Shortest active GHRH fragment | Short-duration pulsatile |
| CJC-1295 No DAC | 29 AA | 4-substitution stabilised GHRH analogue | Short-duration pulsatile |
| CJC-1295 With DAC | 29 AA | DAC maleimide — albumin conjugation | Prolonged (albumin-bound) |
| Tesamorelin | 44 AA | Full-length + trans-3-hexenoic acid (DPP-IV resistant) | Full-sequence GHRHR engagement |
Research context: Tesamorelin is an investigational synthetic GHRH analogue studied in scientific research involving GHRHR signalling, DPP-IV enzymatic stability, and full-length GHRH analogue pharmacology. It has not been authorized by Health Canada for human or veterinary use.
Available Formats
10mg — lyophilized powder
10mg — lyophilized powder
| Format | Net Quantity | Physical Form |
|---|---|---|
| Tesamorelin 10mg | 10 mg / vial | Lyophilized powder |
Sourced from a verified batch. Quantity for use should be determined based on your specific in vitro research protocol by qualified research personnel.
Laboratory Storage
Controlled storage conditions for lyophilized material
Controlled storage conditions for lyophilized material
Store sealed lyophilized material under controlled laboratory conditions in accordance with validated institutional SOPs and applicable technical documentation. Protect from light and moisture. As a relatively large 44-AA peptide, Tesamorelin should be handled with care to avoid mechanical degradation upon reconstitution in the laboratory setting. Handling conditions should be established by qualified research personnel in accordance with the specific experimental protocol.
Note: No preparation, reconstitution, or administration instructions are provided. This compound is supplied for in vitro laboratory research use only. All handling must be conducted by qualified personnel following institutional safety protocols.
Research Literature
Scientific references & related resources
Scientific references & related resources
Tesamorelin Research Peptide Overview — NexPept compound overview and in vitro research context
PubMed — Tesamorelin / TH9507 — peer-reviewed scientific literature on this compound and GHRH analogue pharmacology
Research Peptides in Canada — sourcing and research context for Canadian laboratories
What Are Research Peptides? — peptide classification and in vitro research context
This product is supplied exclusively for in vitro laboratory and non-clinical research use by qualified research personnel. It is not authorized by Health Canada for human or veterinary use. No therapeutic, clinical, or health claims are made.
This material must not be administered to humans or animals. No dosage, preparation, reconstitution, or administration instructions are provided or implied. All handling and use must be conducted by qualified personnel in accordance with applicable institutional policies and legal requirements.
Be the first to review “Tesamorelin 10mg”
Related products
Reviews
There are no reviews yet.